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Formation of the reactive amodiaquine quinoneimine (AQ-QI) and N-desethylamo-
diaquine quinoneimine (DEAQ-QI) plays an important role in the toxicity of the anti-
malaria drug amodiaquine (AQ). Glutathione conjugation protects against AQ-induced
toxicity and GSTP1 is able to conjugate its quinoneimine metabolites AQ-QI and DEA-
QI with glutathione. In this study, HepG2 cells transiently transfected with the human
GSTP1 construct were utilized to investigate the protective effect of GSTP1 in a cellular
context. HepG2 cells were exposed to synthesized QIs, which bypasses the need for
intracellular bioactivation of AQ or DEAQ. Exposure was accompanied by decreased
cell viability, increased caspase 3 activity, and decreased intracellular GSH levels. Using
high-content imaging-based BAC-GFP reporters, it was shown that AQ-QI and DEAQ-
QI specifically activated the endoplasmic reticulum (ER) stress response. In contrast,
oxidative stress, DNA damage, or inflammatory stress responses were not activated.
Overexpression of GSTP1 resulted in a two-fold increase in GSH-conjugation of the QIs,
attenuated QI-induced cytotoxicity especially under GSH-depletion condition, abolished
QIs-induced apoptosis but did not significantly inhibit the activation of the ER stress
response. In conclusion, these results indicate a protective role of GSTP1 by increasing
enzymatic detoxification of AQ-QI and DEAQ-QI and suggest a second protective
mechanism by interfering with ER stress induced apoptosis.
Keywords: amodiaquine, quinoneimine, cytotoxicity, endoplasmic reticulum stress, human glutathione
S-transferases P1
Abbreviations: AQ, amodiaquine; AQ-SG, 5′-glutathion-S-yl-amodiaquine; AQ-QI, amodiaquine-quinoneimine; BSO,
L-buthionine-sulfoximine; CDNB, 1-chloro-2, 4-dinitrobenzene; CYP, cytochromes P450; DEAQ, N-desethylamodiaquine;
DEAQ-SG, 5′-glutathion-S-yl-N-desethylamodiaquine; DEAQ-QI, N-desethylamodiaquine-quinoneimine; DMEM,
Dulbecco’s modified Eagle medium; DMF, N,N-dimethylformamide; ER, endoplasmic reticulum; FBS, fetal bovine serum;
GSH, glutathione; GSSG, glutathione disulfide; GST, glutathione S-transferase; H2O2, hydrogen peroxide; HClO4, perchloric
acid; HRP, horseradish peroxidase; NQO1, NAD(P)H:quinone oxidoreductase 1; NAPQI, N-acetyl-p-benzoquinonimine;
PBS, phosphate-buffered saline; QI, quinoneimine.
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INTRODUCTION
Amodiaquine is a potent anti-malaria drug, however, rare
but life-threatening idiosyncratic hepatotoxicity (1/15,500
patients) and agranulocytosis (1/2000 patients) have restricted
its therapeutic use (Olliaro and Mussano, 2003; Walgren et al.,
2005). Currently, AQ is forbidden for prophylactic use and
is only prescribed in combination therapy with artesunate,
as recommended by WHO (2015). AQ undergoes rapid and
extensive hepatic metabolism to its pharmacologically active
metabolite DEAQ, predominantly by cytochrome P450 2C8
(CYP2C8) (Li et al., 2002). Both AQ and DEAQ are prone
to enzymatic oxidation leading to the formation of AQ-QI
and DEAQ-QI (Lobach and Uetrecht, 2014; Zhang et al.,
2017b). These quinonemines (QIs) can rapidly and irreversibly
modify proteins (Maggs et al., 1987; Tingle et al., 1995;
Lohmann and Karst, 2007) (Figure 1). Such haptenated proteins
can disrupt protein folding or function and lead to direct
toxicity, or can be recognized as ‘non-self ’ leading to immune-
mediated toxicity (Cho and Uetrecht, 2017). Congruently,
cellular studies demonstrated a significant contribution of
AQ bioactivation to AQ cytotoxicity in isolated hepatocytes
(Tafazoli and O’Brien, 2009; Peyre et al., 2015) and in neutrophils
(Naisbitt et al., 1998). Nevertheless, although it is generally
accepted that reactive metabolite formation plays an important
role in AQ-induced toxicity (Srivastava et al., 2010; Cho and
Uetrecht, 2017), the underlying mechanisms and pathways
involved remain unclear. So far, identified contributing
factors include oxidative metabolism (either by CYPs or
peroxidases/hydrogen peroxide), depletion of cellular GSH,
protein carboxylation, mitochondrial disturbances, reactive
oxygen species formation, and lipid peroxidation (Naisbitt et al.,
1998; Tafazoli and O’Brien, 2009; Heidari et al., 2014; Peyre et al.,
2015).
Glutathione S-transferases are important enzymes that
catalyze the conjugation reaction between GSH and chemically
reactive drug metabolites. Furthermore, GSTs are additionally
identified as regulators of cellular signaling pathways, thereby
influencing cell proliferation or apoptosis (Tew and Townsend,
2012; Board and Menon, 2013). GSH-conjugation by GSTs
has been shown in vitro with chemically reactive metabolites
derived from several drugs displaying idiosyncratic toxicity,
including troglitazone, acetaminophen, clozapine, and diclofenac
(Dragovic et al., 2010; Okada et al., 2011; Vredenburg et al.,
2014; den Braver et al., 2016). We recently demonstrated that
GSTs, in particular GSTP1, exhibit high activity in catalyzing
FIGURE 1 | The relationship between AQ metabolism and toxicity. AQ to its major metabolite DEAQ is predominantly catalyzed by CYP2C8 and forms DEAQ (Li
et al., 2002). AQ and DEAQ are bioactivated to their corresponding reactive quinoneimine (QI), catalyzed by CYP3A4, CYP2D6, CYP2C8, and CYP2C9 (Zhang et al.,
2017b). Protein-reactive QIs of AQ and DEAQ can bind to cellular proteins and subsequently lead to toxicity (Harrison et al., 1992; Naisbitt et al., 1998). Reactive QIs
can be detoxified by conjugation reaction with glutathione, which is catalyzed by GSTs, and by reduction reaction catalyzed by human NQO1 (Zhang et al., 2017a).
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the GSH-conjugation of AQ-QI and DEAQ-QI using purified
human GSTs (Zhang et al., 2017a). However, whether GSTs can
protect against AQ-QI- and DEAQ-QI-induced cytotoxicity has
not been evaluated. Nevertheless, several cellular studies have
suggested the protective roles of chemical anti-oxidants, such
as GSH, as well as drug metabolizing enzymes, such as NQO1
and UDP-glucuronosyltransferases (UGTs), against AQ-induced
cytotoxicity (Tafazoli and O’Brien, 2009; Heidari et al., 2014).
HepG2 cells have been used for decades as a test system
for studies involving hepatotoxic compounds. However, basal
levels of phase I and most phase II drug metabolizing enzymes
in HepG2 cells are very low compared to human hepatocytes
(Wilkening et al., 2003; Sison-Young et al., 2015). Upon
transfection or transduction with genes encoding for one or
multiple drug metabolizing enzyme genes, HepG2 cells have
been shown to be a valuable model system to study the role of
bioactivating enzymes in the cytotoxicity of toxicants (Vignati
et al., 2005; Hosomi et al., 2011; Iwamura et al., 2011; Tolosa et al.,
2013; Xuan et al., 2016). Thus, in the present study HepG2 cells
were utilized in combination with transient transfection of the
human GSTP1 gene.
The aims of the present study are (i) to characterize
the mechanisms and cellular pathways of toxicity induced
by reactive QIs of AQ; and (ii) to evaluate the ability of
GSTP1 in protecting against AQ-QI- and DEAQ-QI-induced
cytotoxicity. To this end, we evaluated multiple cellular
parameters including loss of cell viability, caspase 3 activation,
GSH-conjugate formation, GSH homeostasis, and cellular stress
response pathway activation in mock- and GSTP1-transfected
HepG2 cells. Particularly, the activation of adaptive stress
response pathways by AQ-QI and DEAQ-QI was elucidated
using high-content imaging-based BAC-GFP toxicity assays.
To circumvent the need for intracellular bioactivation of
AQ or DEAQ by CYPs, the toxic effects of the synthetic
chemically reactive metabolites AQ-QI and DEAQ-QI were
studied. This study identified ER as the major target for QIs-
induced perturbations and a significant protective role of GSTP1
by alleviating loss of cell viability, enhancing detoxification
of reactive QIs, and attenuating apoptosis. We propose a
model to illustrate the bifunctional potential of GSTP1 in
protecting cells from chemically reactive metabolites targeting
the ER.
MATERIALS AND METHODS
Caution
The quinoneimines are potential highly-toxic and protein-
reactive compounds. Handling requires suitable personal
protections such as gloves and safety glasses.
Chemicals and Reagents
Amodiaquine dihydrochloride was obtained from ICN
Biomedicals (Aurora, OH, United States), DEAQ was obtained
from BD Biosciences (Franklin Lakes, NJ, United States). BSO,
resazurin, and CDNB were purchased from Sigma-Aldrich
(Zwijndrecht, Netherlands). AQ-SG) and DEAQ-SG references
were synthesized and quantified as described before (Zhang et al.,
2017b). Recombinant GSTP1-1 reference was obtained from
earlier study in our group (Zhang et al., 2017a).
HepG2 cells were obtained from European Collection of Cell
Cultures (ECACC, Salisbury, United Kingdom). DMEM and PBS
were purchased from Lonza (Switzerland). FBS was purchased
from PAA Laboratories (Austria). GenJet In Vitro DNA
Transfection Reagent and buffer were purchased from Tebu-bio
(Heerhugowaard, Netherlands). Caspase 3 substrate Ac-DEVD-
AMC was purchased from Enzo Life Sciences (Brussels, Belgium).
Synthesis of Amodiaquine Quinoneimine
(AQ-QI) and Desethylamodiaquine
Quinoneimine (DEAQ-QI)
Synthesis of AQ-QI and DEAQ-QI was adapted from a method
published previously, with a few modifications (Harrison et al.,
1992). Briefly, silver oxide was prepared by mixing one equivalent
of silver nitrate and 2.5 equivalents of sodium hydroxide in
aqueous solution and the solution was stirred on ice for 15 min.
The formed silver oxide precipitate was filtered and washed
with acetone under vacuum and the resulting dried silver oxide
was ready for the subsequent QI synthesis. An excessive (five
equivalents) amount of freshly prepared silver oxide was added
to one equivalent of AQ or DEAQ in anhydrous chloroform
and the mixture was stirred under nitrogen protection for
1 h at room temperature. The formed QIs of AQ and DEAQ
were concentrated in vacuo and then applied to a silica-
60 column to remove the tracing AQ or DEAQ. Identity
of synthetic AQ-QI and DEAQ-QI was verified by mass
spectrometry and the purities were above 95% (Supplementary
Figure S1), as determined by HPLC-UV and LC-TOF-MS (Zhang
et al., 2017b). AQ-QI and DEAQ-QI were dissolved in DMF,
stored at −80◦C and protected from light to prevent possible
degradation.
Cell Culture
HepG2 cells were cultured in collagen-coated plates and main-
tained in DMEM containing 10% FBS, 1% penicillin/-
streptomycin (PAA Laboratories, Austria), 1% ultraglutamine
(Lonza, Switzerland) and 1% non-essential amino acids (Sigma-
Aldrich, Germany). Cells were incubated at 37◦C in 5% CO2
and 95% humidity and were used up to passage 25. Cells were
passaged upon reaching 80% confluency using Trypsin-EDTA
(Lonza, Switzerland).
Transient Transfection of Human GSTP1
Gene
After plating on collagen-coated plates for 24 h, HepG2
cells were transiently transfected with 0.1 µg/1 × 104 cells
hGSTP1 expression plasmid (SC119655, Origene, Rockville, MD,
United States) or accompanying empty pCMV6-XL5 vector
(pCMV6-XL5) using the GenJet In Vitro Transfection Reagent
for HepG2 cells (SignaGen, Rockville, MD, United States)
according to the manufacturer’s instructions. At 18 h after
transfection, medium was replaced and cells were cultured for an
additional 30 h prior to incubations.
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GSTP1 Activity Assay
HepG2 cells were plated on collagen-coated 6-well plates at
3 × 105 cells per well and transfected as described in the above
section. At 48 h post-transfection, cells were harvested in ice-
cold PBS using Trypsin-EDTA (Lonza, Switzerland), centrifuged
at 1000 × g for 3 min, and washed with ice-cold PBS. Cell pellets
were re-suspended in 100 µL PBS. Suspended cells were lysed
with three freezing-thaw cycles in liquid nitrogen and subsequent
ultra-sonication. Cell lysates were obtained with centrifugation
at 14000 rpm for 75 min. GSTP1 activity was measured in
the supernatant using CDNB as a substrate according to the
method described by Habig et al. (1974). GST concentrations in
HepG2 cell lysate were estimated based on the specific activity
of recombinant GSTP1-1 references. Protein concentrations were
determined using the bicinchoninic acid method with bovine
serum albumin as standard (Thermo Fisher Scientific, Waltham,
MA, United States). Activity assay was carried out after each
GSTP1 transfection as validation for the transfection efficiency.
Cell Viability Assay
HepG2 cells were plated on collagen-coated 96-well plates at the
density of 1 × 104 per well in 0.1 mL DMEM. When applicable,
cells were transfected 24 h later as described above. At 48 h
after seeding cells were treated without or with 500 µM BSO
for 24 h, which reduced GSH levels by more than 90% (data
not shown). At 72 h after seeding medium was replaced for
DMEM without FBS containing test compound. The percentage
of organic solvent (DMF) was kept constant at 0.5%. This
DMF concentration didn’t reduce cell viability under non-BSO
pretreatment condition and reduced cell viability less than 5%
under BSO pretreatment condition (Supplementary Figure S2).
Cells were incubated with QIs or parent compounds for 2.5 h,
based on the time-dependency of QIs-induced loss of cell viability
(Supplementary Figure S3). Following treatment medium was
replaced and cell viability was assessed after 16 h (Naisbitt et al.,
1998) by the resazurin reduction assay as described before (Sison-
Young et al., 2017).
Determination of Caspase 3 Activity
Cells were plated on black, clear-bottomed collagen-coated 96-
well plates at the density of 2 × 104 per well in 0.1 mL DMEM.
At 24 and 48 h after seeding, cells were respectively transfected
and treated without or with 500 µM BSO as described above.
At 48 h following transfection HepG2 cells were treated with
0.1 mL DMEM without FBS containing 50 µM AQ-QI or 30 µM
DEAQ-QI for 16 h. Final concentrations of DMF were 0.5%. As a
positive control for apoptosis, tamoxifen (50 µM) was included
(Mandlekar and Kong, 2001). Following incubation, caspase 3
activity was measured using the fluorogenic substrate AC-DEVD-
AMC as described before (Carrasco et al., 2003). Briefly, 50 µL
of caspase assay mixture containing 150 mM HEPES, pH 7.4,
450 mM NaCl, 150 mM KCl, 30 mM MgCl2, 1.2 mM EGTA,
1.5% Nonidet P40, 0.3% CHAPS, 30% sucrose, 150 µM caspase
3 substrate DEVD-AMC, 30 mM DTT, and 3.0 mM PMSF was
directly added to HepG2 cells. Plates were incubated at 37◦C for
2 h and then fluorescence was measured with excitation at 360 nm
and emission at 460 nm using a ClarioStar Monochromator
Microplate Reader (BMG LABTECH, Ortenberg, Germany). Raw
fluorescence values were corrected for background fluorescence,
which was measured in wells without cells containing only
medium, one-step assay buffer and test compound.
Metabolism of AQ-QI and DEAQ-QI in
HepG2 Cells
HepG2 cells were plated on collagen-coated 24-well plates at the
density of 6× 104 per well in 1 mL DMEM. Cells were transfected
at 24 h after seeding and subsequently treated without or with
BSO at 24 h after transfection, as described above. At 24 h after
BSO treatment, HepG2 cells were exposed to 50 µM AQ-QI or
30 µM DEAQ-QI in DMEM medium without FBS for 2.5 h.
Incubations were terminated by addition of ice-cold perchloric
acid at a final concentration of 1% and plates were kept on ice
for 10 min. Cell lysates were transferred to Eppendorf tubes and
debris was removed by centrifugation at 14000 rpm for 20 min
at 4◦C. Supernatants were filtered over 0.2 µm filters and stored
at −20◦C until analysis. GSH-conjugates of AQ-QI and DEAQ-
QI were analyzed and quantified by HPLC-UV, as described
previously (Zhang et al., 2017b).
Assessment of Cellular GSH and GSSG
Content
To investigate the GSH and GSSG content in GSTP1- and mock-
transfected HepG2 cells, concentrations of total GSH and GSSG
were measured using the GSH/GSSG-GloTM Glutathione Assay
kit (Promega, Madison, WI, United States). Cells were plated in
collagen-coated 96-well plates at the density of 2 × 104 per well
in 0.1 mL DMEM. Transfection, BSO treatment, and exposure
of AQ-QI and DEAQ-QI were identical as described in section
“Transient Transfection of Human GSTP1 Gene” and “Cell
Viability Assay.” After exposure the medium was gently removed
and the later steps were conducted according to manufacturer’s
manual.
Stress Reporter Assay of AQ-QI and
DEAQ-QI
To identify the stress response pathways upon AQ-QI and
DEAQ-QI exposure, oxidative stress response (SRXN1-GFP), ER
stress response (CHOP-GFP), inflammation response (ICAM1-
GFP), and DNA damage response (p21-GFP) pathways were
measured with a high-content image-based BAC-GFP stress
responses reporter assay (Wink et al., 2014, 2017).
HepG2-based reporter cells were generated by Bacterial
Artificial Chromosome tagging as described previously (Poser
et al., 2008) and have been characterized previously (Wink et al.,
2017). The modified HepG2 cells originated from HepG2 wild-
type cells acquired from ATCC (clone HB8065). The cells were
plated on collagen-coated 96-well plates at the density of 2× 104
per well in 0.1 mL DMEM, treated subsequently as described
above.
Levels of GFP-tagged stress proteins were monitored using
a Nikon TiE2000 confocal laser microscope (lasers: 488 and
408 nm), equipped with a perfect focus system, a controlled
Frontiers in Pharmacology | www.frontiersin.org 4 April 2018 | Volume 9 | Article 388
fphar-09-00388 April 16, 2018 Time: 17:59 # 5
Zhang et al. GSTP1 Protection in HepG2 Cells
temperature (37◦C) and CO2 (5%) and an automated stage.
Prior to imaging, HepG2 cells were stained with 100 ng/mL
Hoechst33342 to visualize the nuclei. After 45 min of Hoechst33342
staining, medium was replaced with medium containing the
different concentrations of AQ-QI, DEAQ-QI, AQ, and DEAQ
and monitored for 24 h. Quantification of GFP-tagged stress
proteins and data handling were conducted as previously
described (Wink et al., 2017).
Statistical Analysis
Statistical analysis was conducted using Prism (version 5.0). Data
were considered significantly different between groups when
p< 0.05, which was calculated using the Student’s t-test (unpaired
samples, two-tailed, unequal variance).
For the statistics of stress reporter assay data, R (3.3.2) (R Core
Team, 2017) and nlme (Pinheiro et al., 2009) (nlme: Linear and
Nonlinear Mixed Effects Model) was used to perform a linear
mixed effect model for longitudinal data with the following call:
lme [value ∼ time ∗ treatment_dose, random = ∼time | plateID,
correlation = corAR1 (form = ∼1 |plateID)]. As fixed effects
we added time and treatment-dose effects with interaction. As
random effects, we had intercepts for plateID (replicates), as well
as by-plateID random slopes for the effect of time. Correlation
analysis was performed with corAR1, which describes the
within group correlation structure as an autoregressive process
of order 1, and accounts for correlation between adjoining
observations.
Each treatment was compared to the vehicle (DMF) control
treatment in either mock or GSTP1 cells. p-values below 0.05 (∗),
0.01 (#), and 0.001 (¶) were considered as significant.
RESULTS
Validation of Transfection of GSTP1 in
HepG2 Cells
To evaluate the role of GSTP1 in protecting against QIs-induced
cellular perturbations, HepG2 cells were transiently transfected
with a DNA construct containing the human GSTP1 cDNA
behind a CMV-promoter. GST activities in mock- and GSTP1-
transfected HepG2 cells were characterized by measuring CDNB
conjugation to GSH in total cell lysates (Table 1). A 29-
fold increase in CDNB conjugation was observed in GSTP1-
transfected cells. GSH depletion in transfected HepG2 cells by
BSO-treatment slightly decreased GSTP1 activity in cell lysates.
By using the specific activity of purified recombinant GSTP1, the
GSTP1 protein concentration in transfected cells was estimated
at 40–51 µg/mg cytosolic protein. As GSTP1 appears not to be
TABLE 1 | Specific activity of GST in HepG2 cells transfected with empty vector
and human GSTP1 gene.
Mock,
No BSO
GSTP1,
No BSO
Mock,
BSO
GSTP1,
BSO
Activity (nmol/min/mg
cytosolic protein)
14 ± 2 400 ± 13 19 ± 5 317 ± 15
expressed in HepG2 cells (Sison-Young et al., 2015), the low
activity of CDNB conjugation in lysates from mock-transected
cells is most likely due to other GST isoforms (Hao et al., 1994;
Scharmach et al., 2009).
Protection by GSTP1 Against AQ-QI and
DEAQ-QI Cytotoxicity
To investigate the protective effects of GSTP1 under normal
and GSH-depleted conditions, BSO was used to disrupt GSH
synthesis. BSO treatment alone did not significantly decrease cell
viability (data not shown) and had no profound effect on the
cytotoxicity of AQ or DEAQ (Figure 2). At 300 µM, AQ and
DEAQ decreased cell viability with approximately 15 and 70%.
Cytotoxicity of AQ-QI and DEAQ-QI was time-dependent
during the first 3 h of exposure (Supplementary Figure S3).
Longer incubation times did not increase cytotoxicity. In
subsequent experiments, cells were therefore exposed to the
synthetic QIs for 2.5 h. AQ-QI and DEAQ-QI showed a
comparable dose–response (Figure 2). GSH depletion lowered
IC50 values for both AQ-QI (from 54 to 20 µM) and DEAQ-QI
(from 40 to 18 µM).
To investigate the cytoprotective role of GSTP1, mock- and
GSTP1-transfected cells were exposed to AQ-QI and DEAQ-QI.
As shown in Figure 3A, under GSH-depleted conditions viability
of GSTP1-transfected cells was significantly higher compared to
that of mock cells after treatment with 25 and 50 µM AQ-QI
or 40 µM DEAQ-QI. Without GSH depletion, viability of mock-
and GSTP1-transfected cells was comparable for all treatments.
Protection Against AQ-QI- and
DEAQ-QI-Induced Apoptosis by GSTP1
To test whether AQ-QI and DEAQ-QI exposure induced
apoptosis and to study the protective potential of GSTP1, activity
of caspase 3 was measured under normal and GSH-depleted
conditions (Figure 4). GSH depletion by BSO treatment did
not significantly increase caspase 3 activity (data not shown).
Without GSH depletion, exposure to both AQ-QI and DEAQ-
QI increased caspase 3 activity by 60%. When intracellular GSH
levels were depleted activation of caspase 3 was less, being 30
and 40% for AQ-QI and DEAQ-QI, respectively. Expression
of GSTP1 prevented QI-induced activation of caspase 3 almost
completely. Of note is that GSTP1 also attenuated caspase
3 activity induced by the positive control tamoxifen by 50%
(Supplementary Figure S4).
GSTP1 Activity in GSH-Conjugation of
AQ-QI and DEAQ-QI
To investigate the intracellular GSTP1-mediated GSH-
conjugation of AQ-QI or DEAQ-QI, AQ-SG, and DEAQ-SG
formation were measured in total lysates directly after QI
exposure. Under non-stressed GSH concentrations, GSH-
conjugation of AQ-QI and DEAQ-QI was twofold higher in
GSTP1-transfected cells (Figure 5A). Under GSH-depleted
conditions, GSH-conjugation was two- and three-fold higher
in GSTP1-transfected cells compared to mock-transfected cells,
for AQ-QI and DEAQ-QI respectively. The concentration
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FIGURE 2 | Fitted dose–response curves of viability of HepG2 cells under treatment of AQ or AQ-QI (A) and DEAQ or DEAQ-QI (B). HepG2 cells were exposed to
test compounds for 2.5 h. GSH depletion was performed by addition of BSO (500 µM) 24 h before the exposure. Cells were recovered overnight and cell viability
was measured by resazurin reduction activity. Results are presented as percentage relative to vehicle controls in respective treatment groups. Each data point
represents the mean ± SD (n = 3).
FIGURE 3 | Effect of GSTP1 in protection against AQ-QI- (A) and DEAQ-QI- (B) induced loss of cell viability. AQ-QI and DEAQ-QI were incubated with 1 × 104
HepG2 cells transiently transfected with mock or GSTP1 gene for 2.5 h. GSH depletion was performed by addition of BSO (500 µM) 24 h before the exposure of
AQ-QI and DEAQ-QI. Cells were recovered overnight and cell viability was measured by resazurin reduction activity. Results were normalized with setting vehicle
controls under each treatment at 100%. Results are presented as mean ± SD (n = 3). Statistical significant differences with corresponding vehicle control are
denoted with ‘a’ and with corresponding mock-transfected control are denoted with ‘b’ using the following p-values: ∗p < 0.05, #p < 0.01, ¶ p < 0.001; analyzed
by Student’s t-test.
of GSH-conjugates was 0.2 to 4% of the initial AQ-QI
concentration and 0.05 to 0.9% of the DEAQ-QI concentration
(Figure 5A). The majority of QIs was reduced back to the
respective parent compound (∼50% of AQ-QI and ∼80%
of DEAQ-QI), presumably by the action of endogenous
antioxidants and/or reductases, e.g., quinone reductases
(Figure 5B).
The Effect of GSTP1 on AQ-QI- and
DEAQ-QI-Induced Alteration on Cellular
GSH Homeostasis
To evaluate whether cellular GSH homeostasis was affected by
QIs, and whether GSTP1 did influence the effects, concentrations
of intracellular GSH and GSSG were quantified following
exposure to synthetic AQ-QI and DEAQ-QI. BSO treatment
decreased intracellular GSH levels from 40 to 0.8 nmol/106
cells, and further decreased below detection limits following QI
exposure (data not shown). Oxidized GSH (GSSG) levels were
not detectable under GSH-depleted conditions. As shown in
Figure 6A, GSH levels decreased to 25–40% of control cells
after AQ-QI or DEAQ-QI treatment, while the intracellular
GSSG concentrations did not increase correspondingly, but
decreased to approximately 45–80% (Figure 6B). Following
AQ-QI or DEAQ-QI treatment, the ratio of reduced GSH to
oxidized GSH decreased accordingly to 40–65% of control cells
(Figure 6C). Compared with mock cells, no apparent differences
in concentrations of reduced or oxidized GSH were observed in
GSTP1-transfected cells.
Activation of Adaptive Stress Responses
by AQ-QI and DEAQ-QI and Effects of
GSTP1
The stress responses induced by AQ-QI and DEAQ-QI exposure
were measured with a high-content image-based BAC-GFP
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FIGURE 4 | Caspase 3 activity in mock- and GSTP1-transfected HepG2 cells following a 2.5 h exposure to 50 µM AQ-QI (A) or 30 µM DEAQ-QI (B) with or without
a 24 h pretreatment with 500 µM BSO. Caspase 3 activity was used as measure for cell death by apoptosis and is presented as percentage relative to respective
vehicle controls in mock-transfected cells. Each bar represents the mean ± SD from three independent experiments. Statistical significant differences with
corresponding vehicle control are denoted with ‘a’ and with corresponding mock-transfected control are denoted with ‘b’ using the following p-values: ∗p < 0.05;
#p < 0.01; ¶ p < 0.001 (Student’s t-test).
FIGURE 5 | Concentrations of GSH-conjugates of AQ-QI (AQ-SG) and DEAQ-QI (DEAQ-SG) (A), AQ (B), and DEAQ (C) in total lysates of mock- and
GSTP1-transfected HepG2 cells. When applicable, pre-exposure of 500 µM BSO was performed 24 h before treatment. Cells were treated with 50 µM AQ-QI or
30 µM DEAQ-QI for 2.5 h, after which GSH conjugates and reduces QIs were analyzed using HPLC. Results are presented as mean ± SD from four independent
experiments.
stress responses reporter assay for oxidative stress, ER stress,
DNA damage stress and inflammatory stress (Wink et al., 2014,
2017). BSO treatment was not included, because this already
induced a significant oxidative stress response (data no shown).
Up to respectively 70 and 40 µM, AQ or DEAQ did not
significantly activate any of the tested stress response pathways,
which is consistent with the limited onset of cytotoxicity by
these compounds (Figure 2). However, exposure to AQ-QI
or DEAQ-QI resulted in a rapid, marked activation of the
ER stress response. Interestingly, all other tested pathways
(oxidative stress, DNA damage, and inflammatory stress) were
not significantly activated by either AQ-QI or DEAQ-QI
treatment (Supplementary Figure S5). As shown in Figure 7,
in mock- and GSTP1-transfected HepG2 cells dose- and time-
dependent up-regulations of CHOP-GFP signal were detected
following treatment with AQ-QI or DEAQ-QI. Although a
minor inhibition of the ER stress response by GSTP1 was
observed (comparing corresponding curves in Figures 7A–D),
no statistical difference was found between mock- and GSTP1-
transfected cells.
DISCUSSION
The contribution of oxidative metabolism of AQ to cytotoxicity
has previously been demonstrated by several studies (Naisbitt
et al., 1998; Tafazoli and O’Brien, 2009; Peyre et al., 2015).
Recently, it was shown that recombinant human GSTs, in
particular GSTP1, significantly contributed to the inactivation of
AQ-derived QIs by catalyzing GSH-conjugation (Zhang et al.,
2017a) (Figure 1). GSTP1 is generally not expressed in human
hepatocytes (Sison-Young et al., 2015), however, expression is
often up-regulated under stress conditions and in tumors (Tew
and Townsend, 2012). GSTP1 is highly expressed in neutrophils
(Fessler et al., 2002), where it may protect against AQ-induced
agranulocytosis. In the present study, GSTP1 was selected as
a model GST to evaluate the protective effects of GSTs in a
cell-based in vitro system.
Glutathione S-transferase activities in mock- and GSTP1-
transfected HepG2 cells were in a similar range as reported
previously in mock- (and GSTP1-)transfected HepG2 cells (Hu
et al., 1999; Gallagher et al., 2007; Peklak-Scott et al., 2008). Low
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FIGURE 6 | Effects of 50 µM AQ-QI and 30 µM DEAQ-QI on intracellular concentrations of reduced GSH (rGSH) (A), GSSG (B), and on the ratio of reduced GSH to
GSSG (C) in HepG2 cells without BSO pretreatment. Mock- and GSTP1-transfected cells were treated with 50 µM AQ-QI or 30 µM DEAQ-QI for 2.5 h, after which
GSH and GSSG levels were quantified as described section “Materials and Methods.” Results are presented as mean ± SD (n = 3).
FIGURE 7 | Time dynamics of CHOP-GFP reporter activation following exposure to AQ-QI (A,B) or DEAQ-QI (C,D). Prior to exposure, HepG2 DDIT3/CHOP-GFP
cells were transfected with empty vector (A,C) or GSTP1 cDNA (B,D). Statistical significant differences with corresponding vehicle control from each group are
denoted with ∗p < 0.05, #p < 0.01, and ¶ p < 0.001; analyzed by linear mixed effect model as described in detail in section “Materials and Methods.”
basal level of CDNB activity observed in mock HepG2 cells likely
resulted from low levels of other GST isoforms, since GSTP1 is
not expressed in HepG2 cells (Sison-Young et al., 2015). The 29-
fold increase of CDNB activity observed in GSTP1-transfected
cells unambiguously demonstrated the over-expression of
functional GSTP1.
We circumvented the need for CYP-mediated bioactivation
of AQ and DEAQ by exposing the cells to the synthetic
Frontiers in Pharmacology | www.frontiersin.org 8 April 2018 | Volume 9 | Article 388
fphar-09-00388 April 16, 2018 Time: 17:59 # 9
Zhang et al. GSTP1 Protection in HepG2 Cells
FIGURE 8 | Proposed model for the toxicity of AQ-QI and DEAQ-QI and GSTP1-mediated protection in HepG2 cells. Reactive moieties in the QIs are indicated in
red. For AQ-QI, R = -CH2CH3; for DEAQ-QI, R = -H. AQ-QI and DEAQ-QI deplete cellular GSH and are conjugated into AQ-SG and DEAQ-SG, respectively. The ER
stress response (CHOP) is activated by QI-mediated protein modification and apoptosis is subsequently induced. GSTP1-mediated protection against reactive QIs of
AQ is due to enhanced GSH-conjugation and inhibition of apoptosis.
AQ-QI and DEAQ-QI, the reactive metabolites of AQ. As
expected, the chemically reactive metabolites were much
more cytotoxic than their respective precursors and displayed
comparable and steep dose-dependent decreases in cell viability
(Figure 2). Cytotoxicity of both QIs increased under GSH-
depleted conditions, confirming that GSH is important as
scavenger by GSH-conjugation and as endogenous antioxidant
(Figure 1). In contrast, caspase 3 activation, a marker for
apoptotic activation, by AQ-QI and DEAQ-QI was higher
without BSO pre-treatment (Figure 4). The difference between
the effects of both QIs on the cell viability (Figure 2) and caspase
3 activation (Figure 4) suggests that upon GSH depletion, the
decrease in cell viability is not only apoptosis dependent but also
most likely depends other cell death pathways, such as necrosis
(Iorga et al., 2017).
IC50 values of QIs under GSH-depleted conditions were
around 20 µM (Figure 2), which is higher than the plasma
concentrations of AQ and DEAQ found in patients, normally
in nanomolar to micromolar ranges (Laurent et al., 1993; Lai
et al., 2009; Scarsi et al., 2014). However, hepatic concentrations
of AQ and DEAQ are likely higher as AQ strongly accumulates
in the liver (Barrow, 1974). Although QI levels in vivo may
be lower, exposure continues for a prolonged period as the
half-life of DEAQ is 10 to 12 days (Krishna and White, 1996;
Rijken et al., 2011). In the current HepG2 cell model, in which
prolonged exposure is not feasible, the use of relatively high QI
concentrations in a short timeframe allows for the identification
of underlying mechanisms and pathways, as has been done
previously in similar studies with hepatic toxicants (Tafazoli and
O’Brien, 2009; Heidari et al., 2014) and other reactive drug
metabolites such as NAPQI (Chia et al., 2010; Kalinec et al., 2014).
The relative contribution of GSTP1 to GSH-conjugation
of both QIs was highest at GSH-depleted conditions, while
in absolute quantities a higher GSTP1-dependent increase of
GSH conjugate formation was seen without BSO pre-treatment
(Figure 5). Additionally, GSTP1-transfected HepG2 cells were
significantly more resistant against the cytotoxicity of both
QIs under GSH-depleted conditions (Figure 3). Together, these
results indicate a more critical role of GSTP1 under low
GSH concentration. The more efficient conjugation of the QIs
to GSH may have reduced covalent modification of cellular
macromolecules, like ER proteins Grp78/Bip (Xu et al., 2015),
microsomal GST (Weis et al., 1992), and PDI (Liu et al., 2005).
GSTP1 itself can also function as a target, as has been shown
for chemically reactive metabolites derived from acetaminophen
(Jenkins et al., 2008) and diclofenac (Boerma et al., 2012).
Although reactive QI formation has been associated with AQ-
induced (cyto)toxicity in vitro (Naisbitt et al., 1998; Tafazoli
and O’Brien, 2009) and in vivo (Christie et al., 1989; Shimizu
et al., 2009), the exact cellular mechanisms and pathways of
AQ-QI and DEAQ-QI toxicity remain poorly understood. For
GSTs, the protective role toward cytotoxicity or mutagenicity
has been shown for many xenobiotics, including environmental
carcinogens, such as polycyclic aromatic hydrocarbons (Hu
et al., 1999; Ahmad et al., 2008; Kabler et al., 2009), anti-tumor
alkylating agents, such as doxorubicin (O’Brien et al., 2000;
Tashiro et al., 2001) and cisplatin (Peklak-Scott et al., 2008), and
hepatotoxic drugs such as diclofenac (Al-Attrache et al., 2016),
isoniazid and acetaminophen (Tolosa et al., 2017). However,
also for GSTs, the mechanisms of protection are not always
clear. More recently, it is becoming well-recognized that a better
understanding of cellular signaling pathways alternation under
toxicological insult will benefit the risk assessment and early
stage prediction of drug toxicity (Jennings et al., 2013). For this
purpose, activation of adaptive stress responses was investigated
for DNA damage (p21), oxidative stress (SRXN1), inflammation
(ICAMI), and ER stress (CHOP) using a HepG2-based GFP-
reporter assay (Wink et al., 2014, 2017). Unexpectedly, activation
of p21, ICAM1, or SRXN1 was not observed (Supplementary
Figure S5), although DNA (Dybing et al., 1984), TRPA1 (Nassini
et al., 2010), and Keap1 (Copple et al., 2008) are known targets
for other QIs. The lack of a DNA damage response may
be a result of the extracellular exposure to QIs. The modest
decrease in GSH/GSSG ratios seen (Figure 6) is consistent
with the lack of activation of an adaptive oxidative stress
response pathway observed here and in a previous study
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(Tafazoli and O’Brien, 2009). As shown in Figure 7, AQ-QI
and DEAQ-QI exposure resulted in activation of the ER stress
response. Many chemicals have been reported to induce ER
stress and subsequently cause toxicity in hepatic and extra-
hepatic cells (Fredriksson et al., 2014; Foufelle and Fromenty,
2016; Ren et al., 2016; Qaisiya et al., 2017), in particular
chemically reactive benzoquinones which may react directly with
ER proteins (Wang et al., 2006; Kalinec et al., 2014). Mild
ER stress assists cells with surviving from intrinsic or external
insults. However, in case of persistent and/or larger ER stress
prevailing over the cellular defensive mechanisms, cell injury and
activation of various pro-apoptotic signaling pathways take place
(Chaudhari et al., 2014) in which CHOP exhibits an essential
role (Oyadomari and Mori, 2004; Tabas and Ron, 2011). The
rapid CHOP activation indicated that cytotoxicity of AQ-QI and
DEAQ-QI was accompanied by the activation of the adaptive ER
stress response pathway and subsequent activation of apoptotic
programs (Fredriksson et al., 2014). The initial insult inflicted
by the QIs, activating CHOP, could not be lowered by GSTP1.
These results indicate that GSTP1 interfered with QI-induced
apoptosis downstream of CHOP activation, or that apoptosis
was additionally activated via a CHOP independent pathway
(Hetz, 2012) with a higher threshold. GSTP1 as a modulator
in cell survival and/or apoptotic signaling pathways has been
well-established (Tew and Townsend, 2012; Board and Menon,
2013). Drug resistance observed in tumor tissues have been
associated with the overexpression of GSTP1, which effectively
blocks JNK signaling pathways (Adler et al., 1999) while specific
inhibitors of GSTP1 induce activation of JNK (Burg et al., 2006).
In the present study, GSTP1-mediated JNK modulation leading
to inhibition of pro-apoptotic signaling pathway may have
contributed to the protective effect of GSTP1 against QIs-induced
cytotoxicity. In line with this hypothesis, activation of caspase 3
by tamoxifen, which is known to cause JNK-mediated apoptosis
(Mandlekar and Kong, 2001), was also significantly attenuated by
GSTP1 (Supplementary Figure S4), which cannot be explained
by GSTP1-mediated inactivation of reactive metabolites in the
absence of bioactivation of tamoxifen in HepG2 cells.
In summary, we identified ER stress as the main adaptive
stress response caused by AQ-QI and DEAQ-QI and evaluated
the protective role of GSTP1 using a transfected HepG2 cell
model. Expression of GSTP1 blocked caspase 3 activation
and increased GSH-conjugation upon AQ-QI and DEAQ-
QI treatment. Furthermore, AQ-QI- and DEAQ-QI-induced
cytotoxicity was reduced in GSTP1-transfected cells under GSH-
depleted conditions. The immediate activation of the adaptive
ER stress response was reduced, but not blocked by GSTP1.
Altogether, as proposed in the model in Figure 8, we conclude
that the protein-reactive QIs of AQ mainly trigger ER stress,
eventually leading to apoptosis in HepG2 cells. The results
indicate a protective role of GSTP1 by enhancing GSH-
conjugation, which might lead to a reduced protein modification,
and suggest a second protective role by interfering with the
unfolded protein response, thereby preventing apoptosis.
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